Analysis of astragaloside IV metabolism to cycloastragenol in human gut microorganism, bifidobacteria, and lactic acid bacteria.
Bioscience, biotechnology, and biochemistry
confidence
Key findings
Astragaloside IV metabolized to cycloastragenol by bifidobacteria and lactic acid bacteria via distinct pathways; no clinical/biological endpoints reported.
View source on PubMed (PMID 35904311) ↗
- Sample size
- Not reported
- Population
- In vitro human gut microorganisms (lactic acid bacteria and bifidobacteria)
- Dosing
- Not reported
- Duration
- Not reported
- Route
- In vitro incubation
- Blinding
- not_reported
- Controls
- none
- Drug class
- telomerase activator
Full abstract
This study investigated different gut bacteria in an anaerobic environment to identify specific candidates that could transform astragaloside IV (AIV) to cycloastragenol (CA). Two representative gut microbes, lactic acid bacteria (LAB) and bifidobacteria, could metabolize AIV to CA. Multiple screenings showed two metabolic pathways to metabolize AIV in two groups of bacteria. LAB metabolized AIV initiated by removing the C-6 glucose, whereas bifidobacteria indicated the initial removal of C-3 xylose. The final products differed between the two groups as bifidobacteria showed the production of CA, whereas LAB demonstrated preferential production of 20R, 24S-epoxy-6α, -16β, -25-trihydroxy-9, -19-cycloartan-3-one (CA-2H).